A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Name: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Published: 2016
License: Public Domain

Celgene · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

ace anemia

myelodysplastic syndromes, luspatercept, transfusion dependent, lower risk, low risk, esa refractory, esa intolerant, esa ineligible, ace-536, anemia, ring sideroblasts, require red blood cell transfusions

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 968551
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.